sglt2 inhibitors and glp-1 receptor agonists together vs. to Treat the Heart, the Kidneys the Brain SGLT-2 Inhibitors and GLP-1 Agonists:
Description
12 mg: -24.2% body weight at 48 weeks

The third study added immobilization, a well-established stimulus for muscle wasting, to see if not exercising the muscle would reveal any hidden harmful effects of GLP-1-based drugs on muscle mass

Understanding these medications, their mechanisms, and their barriers is essential to improving patient access and adherence

Conflict of interest Author AA has received consulting fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz and Takeda

this mindset fuels healthy habits and sustained enjoyment
